Real‐world outcomes of <scp>anti‐EGFR</scp> therapy in advanced non–small cell lung cancer <scp>EGFR</scp> mutated in Peru-Reference-Cited by-同舟云学术

Real‐world outcomes of anti‐EGFR therapy in advanced non–small cell lung cancer EGFR mutated in Peru

Published:2022-11-11 Issue:1 Volume:14 Page:61-67
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Galvez‐Nino Marco¹²^ORCID,Ruiz Rossana¹³^ORCID,Roque Katia¹²^ORCID,Coanqui Ofelia¹²^ORCID,Valdivieso Natalia¹^ORCID,Olivera Mivael¹^ORCID,Ganti Apar Kishor⁴^ORCID,Mas Luis¹⁵^ORCID

Affiliation:

1. Department of Medical Oncology Instituto Nacional de Enfermedades Neoplásicas Lima Peru

2. Escuela Profesional de Medicina Humana Universidad Privada San Juan Bautista Lima Peru

3. Universidad Científica del Sur Lima Peru

4. VA Nebraska Western Iowa Health Care System, University of Nebraska Medical Center Omaha Nebraska USA

5. Universidad Peruana Cayetano Heredia Lima Peru

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14714

Reference27 articles.

1. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

2. The Effect of Advances in Lung-Cancer Treatment on Population Mortality

3. Lung cancer

4. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

5. The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SYNGR2 plays a tumor-promoting role in lung adenocarcinoma through PI3K-AKT signaling pathway;2023-10-28